Heart failure patients who had beads <a href="http://benhvienhoanmy.net/nhung-trieu-chung-benh-tim-to.html">tim hieu ve benh tim to tim nho</a> About 85 percent of patients who received the gel implants displayed only slight or no limitations in physical activity during a one-year follow-up, compared with only 25 percent of patients in a comparable control group.
Blood oxygen levels also continue to improve in these patients, and they are able to walk hundreds of feet farther, said lead researcher Dr. Douglas Mann, chief of the cardiovascular division at Washington University School of Medicine and a cardiologist-in-chief at Barnes Jewish Hospital in St. Louis.
The findings from a clinical trial update were published recently in theEuropean Journal of Heart Failure.<a href="http://benhvienhoanmy.net/bai-thuoc-nam-chua-benh-thieu-mau-co-tim.html">thuoc nam thieu mau co tim</a> Based on these results, the U.S. Food and Drug Administration has authorized a larger-scale clinical trial of Algisyl-LVR. It will involve 240 patients with advanced heart failure, Mann announced last week at the American Heart Association meeting in Orlando, Fla.
Heart experts at the meeting said the initial results <a href="http://benhvienhoanmy.net/bai-thuoc-nam-chua-benh-thieu-mau-co-tim.html">thuoc nam chua thieu mau co tim</a> appear impressive, but they also expressed concern over the death rate among patients who received the gel implants.
"We really need to iron out the mortality risk associated with this device," said Dr. Lori Mosca, director of preventive cardiology at New York-Presbyterian Hospital and medical director of the Columbia University Center for Heart Disease Prevention in New York City.
Không có nhận xét nào:
Đăng nhận xét